Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 11/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1306805 | 1.00 | P2RY1 (0.40) | P2RY1CA12CA2CA9CA14 | |
| SCHEMBL397028 | 0.81 | ALDH1A1 (0.48) | P2RY1TDP1ALDH1A1GAACYP1A2 | |
| SCHEMBL30500977 | 0.77 | ALDH1A1 (0.48) | P2RY1CA2NISCHHTTNPSR1 | |
| SCHEMBL127278 | 0.77 | ALDH1A1 (0.48) | P2RY1CA2NISCHHTTNPSR1 | |
| SCHEMBL1306618 | 0.76 | ALDH1A1 (0.46) | HTTNPSR1TDP1ALDH1A1GAA | |
| SCHEMBL11275925 | 0.76 | PTGS1 (0.50) | CA12CA2CA9CA14HTT | |
| SCHEMBL17678671 | 0.76 | CA12 (0.39) | CA12CA2CA9CA14HTT | |
| SCHEMBL1307934 | 0.75 | P2RY1 (0.36) | P2RY1CA12CA2CA9CA14 | |
| SCHEMBL14008970 | 0.74 | LMNA (0.49) | P2RY1TDP1ALDH1A1LMNA | |
| SCHEMBL9853590 | 0.73 | CYP3A4 (0.46) | CA12CA2CA9CA14HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269120-A1 | Method for Treating an Autoimmune and Inflammatory Disease | CELLESTIA BIOTECH AG (CH) | 2024-08-15 | — | — | US | claimed |
| EP-4346816-A2 | COMPOUNDS FOR USE IN A METHOD FOR TREATING AN AUTOIMMUNE AND INFLAMMATORY DISEASE | Cellestia Biotech AG (CH) | 2024-04-10 | — | — | EP | claimed |
| CN-117794536-A | Compounds for use in methods of treating autoimmune and inflammatory diseases | 塞莱斯蒂亚生物技术股份公司 | 2024-03-29 | — | — | CN | claimed |
| WO-2022253794-A2 | METHOD FOR TREATING AN AUTOIMMUNE AND INFLAMMATORY DISEASE | CELLESTIA BIOTECH AG (CH) | 2022-12-08 | — | — | WO | claimed |
| US-20240269120-A1 | Method for Treating an Autoimmune and Inflammatory Disease | CELLESTIA BIOTECH AG (CH) | 2024-08-15 | — | — | US | disclosed |
| EP-4346816-A2 | COMPOUNDS FOR USE IN A METHOD FOR TREATING AN AUTOIMMUNE AND INFLAMMATORY DISEASE | Cellestia Biotech AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794536-A | Compounds for use in methods of treating autoimmune and inflammatory diseases | 塞莱斯蒂亚生物技术股份公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2022253794-A2 | METHOD FOR TREATING AN AUTOIMMUNE AND INFLAMMATORY DISEASE | CELLESTIA BIOTECH AG (CH) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269120-A1 | Method for Treating an Autoimmune and Inflammatory Disease | SERPINB1, TNF, MPO | P2RY1 878/4885CA12 294/4885CA2 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.